Amniotics AB today announces that Gerton Jönsson is appointed as new CFO. Gerton Jönsson will take up the position on May 2, 2023 and succeeds Johny Humaloja who will leave his position after handover.

Gerton Jönsson has worked for around than 20 years as an accounting consultant for both large international groups and for smaller companies and has also been acting CFO at Doxa. He has broad experience of the various elements required of a CFO at a smaller listed company.

"I look very much forward welcoming Gerton Jönsson as the new CFO of Amniotics. With his broad expertise and experience, he will be a great asset to Amniotics in our continued development. At the same time, I would like to take this opportunity to thank Johny Humaloja for his valuable contributions to Amniotics, not least in connection with the IPO and subsequent capital raising, and wish him good luck in the future", says Marcus Larsson, CEO of Amniotics.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now in clinical phase with the leading drug candidate PulmoStem™. The company is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm.
Amniotics Certified Adviser at First North is Redeye AB, e-post: certifiedadviser@redeye.se.
Learn more at www.amniotics.com. 

Attachments

Amniotics appoints Gerton Jönsson as new CFO

© Modular Finance, source Nordic Press Releases